Nanolattix
- Biotech or pharma, therapeutic R&D
Nanolattix BIO presentation: Monday, June 16th, 2:15pm, room 154
Nanolattix focuses on ADC/RDC oncology therapeutics. T320-ADC has received IND approval in the US, Australia, and China. Received Orphan Drug Designation for Pancreatic Cancer in the US (fast to market, 7 years market exclusivity post-approval). Phase 1 clinical trials began in March 2025. ADCs (2), bispecific ADCs (8), and RDC (8), drug candidates with promising preclinical data. Various indications in solid tumor, including Lung, Pancreatic, Colorectal, Gastric, etc.
Nanolattix is seeking collaborative licensing and development partnerships for global expansion.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}